A new report by DART Markets forecasts the overall world market for treating age-related macular degeneration (AMD or ARMD), diabetic retinopathy (DR) and other disorders of the retina will reach $17.38bn in 2020. That revenue forecast and others appear in Retinal Diseases: Wet and Dry AMD, Diabetic Retinopathy Market 2016-2026: Aflibercept, Ranibizumab, Bevacizumab, Verteporfin, Ocriplasmin, Anti-VEGF, Anti-PDGF, published in July 2016.
This 208-page report provides quantitative and qualitative information on 10-years revenue forecasts to 2026 at overall world market, disease submarkets, product (brand) and national market level presented in 121 charts and discussion. The study gives revenue predictions to 2026 for four therapeutic submarkets at world level:
- Wet age-related macular degeneration (wAMD)
- Dry AMD (dAMD)
- Diabetic retinopathy (DR)
- Other retinal diseases (grouped forecast).
The study also provides revenues and forecast of five prominent drugs to 2026:
This report discusses the competitive landscape in the retinal diseases drugs market, which includes discussion on SWOT, STEP, Leading Companies, and M&A activities in this market.
Research, data and analyses cover activities of leading companies in the retinal diseases drugs industry: - Roche
- Other manufacturers and marketers of ophthalmic pharmaceuticals
This new study also discusses leading pipeline candidates for Wet AMD, Dry AMD, and Diabetic Retinopathy, shows two interviews and predicts revenues to 2026 in 11 leading national markets.
The work analyses these national markets:
- EU5 (Italy, Spain, Germany, the UK and France)
- BRIC (Brazil, Russia, India and China)
- Rest of the World
This report also provides a separate chapter on Pricing, Reimbursement, Market Access and Regulations, providing insights on these national markets:
- Emerging Markets
Our reports have been used by over 10K customers, including:
192 pages •
By Transparency Market Research
• Sep 2018
Global Assistive Technologies for Visually Impaired Market: Overview This report analyzes the current and future scenario of the global assistive technologies for visually impaired market. Surge in product development, increase in demand for assistive technologies for visually impaired, and rise in prevalence and causes...
Strabismus Global Clinical Trials Review, H2, 2018 Summary GlobalData’s clinical trial report, “Strabismus Global Clinical Trials Review, H2, 2018" provides an overview of Strabismus clinical trials scenario.This report provides top line data relating to the clinical trials on Strabismus. Report...
185 pages •
By Transparency Market Research
• Aug 2018
Glaucoma Therapeutics Market: Scope and Methodology This report analyzes the current and future prospects of the global glaucoma therapeutics market.The report comprises a comprehensive executive summary, including a market snapshot that provides overall information of various segments. The research is a combination...
Comprehensive Pipeline Review on Ongoing Clinical and Pre-clinical studies Juvenile Macular Degeneration (Stargardt Disease) Drug Development Pipeline Study is the latest publication from VPA Research with comprehensive information of Juvenile Macular Degeneration (Stargardt Disease) pipeline products. The Juvenile Macular Degeneration...
Comprehensive Pipeline Review on Ongoing Clinical and Pre-clinical studies Ocular Hypertension Drug Development Pipeline Study is the latest publication from VPA Research with comprehensive information of Ocular Hypertension pipeline products. The Ocular Hypertension pipeline guide presents complete overview of drugs currently...
Comprehensive Pipeline Review on Ongoing Clinical and Pre-clinical studies Atrophic Macular Degeneration Drug Development Pipeline Study is the latest publication from VPA Research with comprehensive information of Atrophic Macular Degeneration pipeline products. The Atrophic Macular Degeneration pipeline guide presents complete...